SCHEMBL6941364

SCHEMBL6941364

C[C@H](CO)Nc1ccc([N+](=O)[O-])cc1C(=O)NCc1ccc(Oc2ccccc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.51
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
CRHBP P24387 1/20 0.49
CRHR2 Q13324 1/20 0.49
MAPT P10636 3/20 0.46
ALDH1A1 P00352 2/20 0.46
HPGD P15428 1/20 0.46
GAA P10253 2/20 0.46
MMP13 P45452 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MAPK14 Q16539 1/20 0.44
AKR1C3 P42330 1/20 0.44
PPARG P37231 1/20 0.44
PPARD Q03181 1/20 0.44
PPARA Q07869 1/20 0.44
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
TDP1 Q9NUW8 2/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6941371 1.00 FFAR1 (0.51) FFAR1MEN1KMT2ACRHBPCRHR2
SCHEMBL7073454 0.89 MAPT (0.48) MEN1KMT2ACRHBPCRHR2MAPT
SCHEMBL7073458 0.89 MAPT (0.48) MEN1KMT2ACRHBPCRHR2MAPT
SCHEMBL7389851 0.85 MAPT (0.51) FFAR1MEN1KMT2ACRHBPCRHR2
SCHEMBL6942978 0.83 GAA (0.44) MEN1KMT2ACRHBPCRHR2MAPT
SCHEMBL6939382 0.83 GAA (0.44) MEN1KMT2ACRHBPCRHR2MAPT
SCHEMBL6939383 0.82 GABRP (0.51) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL688476 0.82 GABRP (0.51) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL688477 0.82 GABRP (0.51) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL29611681 0.82 GABRP (0.51) MEN1KMT2AMAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1080069-B1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO (JP) 2003-03-19 EP disclosed
US-6384080-B1 TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-05-07 US disclosed
CN-1305454-A Anthranilic acid derivatives as inhibitors of CGMP phosphodiesterase FUJISAWA PHARMACEUTICAL CO (JP) 2001-07-25 CN disclosed
EP-1080069-A1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-03-07 EP disclosed
WO-1999054284-A1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-10-28 WO disclosed